WinstonWınston
Back
Stock

OPKO Health

OPK
26
Medical - Diagnostics & Research · Healthcare
Also trades as: 0KCS.L GBP 0.02 (-1.81%)
Price
$1.63
+0.00 (+0.00%)
Market Cap
$1.22B
Exchange
NASDAQ
Winston Score
26
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Oct 25, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Weak
6/30
Growth
Mixed
5/20
Cash Flow
Weak
0/10
Stability
Mixed
4/10
Valuation
Data not available
0/10
Ownership
Good
10/15
Dividends
Not counted
n/a

25 of 95 counted points = Winston Score 26. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+15.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 648.1M (2021) → 751.1M (2025)

§Winston Score History

The full picture

OPKO Health is a healthcare company that makes diagnostic tests and pharmaceutical drugs. Its biggest business is BioReference Laboratories, one of the largest clinical lab testing services in the U.S., which processes blood tests and other medical tests for doctors and hospitals. OPKO also sells Rayaldee, a prescription drug used to treat vitamin D deficiency in patients with chronic kidney disease.

OPKO makes money by charging for lab tests processed through BioReference and through prescription drug sales. The company operates mainly in the United States, with some international pharmaceutical operations in countries like Israel and Chile. With a market cap around $1 billion and a negative operating margin, OPKO is currently spending more than it earns, which is a key concern for investors. The main risk is that the lab testing business faces intense price pressure from larger competitors like Quest Diagnostics and Labcorp, while the pharmaceutical side depends heavily on growing Rayaldee prescriptions to move toward profitability.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+4.3% YoY

YoY Growth Rate

Slow revenue growth

Reported EPS Growth

+94.7% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.19

30 Jun 2026: $-0.01

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$124M/ year

↑ Rising (+18% vs prior year)

20.4% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

56.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~22 months

$341M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Heavy R&D investment

OPKO Health is putting 20% of revenue into R&D and that number is rising.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
48.9%
Healthy — 48.9% gross margin
Profit after running costs
Operating Margin
-4.3%
Losing money on operations — -4.3%
Return on the money invested
ROCE
-9.5%
Weak — -9.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-11.5%
Shrinking sales (-11.5% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-22.8%
Burning cash (-22.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.33
Conservative — low debt load (0.33)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial